Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This special issue of POZ Focus is dedicated to understanding lipodystrophy among people living with HIV.
Understanding lipodystrophy among people living with HIV, including hard belly and visceral fat.
Lipo can be a constant reminder of living with HIV and can lead to loss of self-esteem and social withdrawal.
This issue discusses lipodystrophy and HIV, including causes and treatments for abnormal changes such as hard belly and visceral fat.
Abnormal body fat changes remain a challenge for many people living with HIV.
A side effect of some HIV meds, lipodystrophy results in a redistribution of fat.
Lipodystrophy, or abnormal changes in fat distribution, is a common problem among people living with HIV.
What is lipodystrophy and what causes it?
New data suggest that an expanding waistline associated with lipodystrophy is associated with decreased mental functioning.
HIV-positive individuals experiencing a loss of muscle mass and an increase in abdominal fat may face an increased risk of death, according to...
Egrifta (tesamorelin), the lipodystrophy treatment approved by the U.S. Food and Drug Administration (FDA) late last year, is now officially a...
HIV might damage cellular mitochondria, the suspected cause of face and body fat loss attributed to older antiretroviral (ARV) medications. Th...
Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from...
A U.S. Food and Drug Administration independent advisory committee is set to review Montreal-based Theratechnologies’ New Drug Application..
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.